Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31221
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKacar, Mark-
dc.contributor.authorSavic, Sinisa-
dc.contributor.authorVAN DER HILST, Jeroen-
dc.date.accessioned2020-05-26T11:50:18Z-
dc.date.available2020-05-26T11:50:18Z-
dc.date.issued2020-
dc.date.submitted2020-04-07T11:48:35Z-
dc.identifier.citationJOURNAL OF INFLAMMATION RESEARCH, 13 , p. 141 -149-
dc.identifier.urihttp://hdl.handle.net/1942/31221-
dc.description.abstractFamilial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1 beta, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.-
dc.language.isoen-
dc.publisherDOVE MEDICAL PRESS LTD-
dc.rights2020 Kacar et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).-
dc.subject.otherfamilial mediterranean fever-
dc.subject.otherCanakinumab-
dc.subject.otheranti-IL1 therapy-
dc.titleThe Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature-
dc.typeJournal Contribution-
dc.identifier.epage149-
dc.identifier.spage141-
dc.identifier.volume13-
local.format.pages9-
local.bibliographicCitation.jcatA1-
dc.description.notesvan der Hilst, JCH (reprint author), Jessa Hosp, Dept Infect Dis & Immun, Stadsomvaart 11, B-3500 Hasselt, Belgium.-
dc.description.notesjeroen.vanderhilst@jessazh.be-
dc.description.othervan der Hilst, JCH (reprint author), Jessa Hosp, Dept Infect Dis & Immun, Stadsomvaart 11, B-3500 Hasselt, Belgium. jeroen.vanderhilst@jessazh.be-
local.publisher.placePO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND-
local.type.refereedRefereed-
local.type.specifiedReview-
dc.source.typeReview-
dc.identifier.doi10.2147/JIR.S206204-
dc.identifier.pmid32210604-
dc.identifier.isiWOS:000520589800001-
dc.identifier.eissn1178-7031-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorKacar, Mark-
item.contributorSavic, Sinisa-
item.contributorVAN DER HILST, Jeroen-
item.fullcitationKacar, Mark; Savic, Sinisa & VAN DER HILST, Jeroen (2020) The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature. In: JOURNAL OF INFLAMMATION RESEARCH, 13 , p. 141 -149.-
item.accessRightsOpen Access-
item.validationecoom 2021-
crisitem.journal.eissn1178-7031-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
kacar.pdfPublished version481.07 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.